Women's Health Medicine
Volume 2, Issue 6 , Pages 24-25, November 2005

Drug therapies for overactive bladder

  • Katrien De Maeyer

      Affiliations

    • Katrien De Maeyer is Specialist Registrar in Obstetrics and Gynaecology at Hinchingbrooke Hospital, UK. She qualified from Katholieke Universiteit Leuven in Belgium and did most of her postgraduate training in the UK.
    • ,
  • Helen Johnson

      Affiliations

    • Helen Johnson is Consultant Gynaecologist at both Hinchingbrooke and Addenbrooke’s Hospitals, UK. She qualified from St Mary’s Hospital Medical School and trained in obstetrics and gynaecology in Yorkshire. Her interests are predominantly in urogynaecology.
    • ,
  • Mark Slack

      Affiliations

    • Mark Slack is Head of Urogynaecology at Addenbrooke’s Hospital, UK.

Abstract 

The cornerstones of current drug therapy for overactive bladder are anticholinergic drugs; oxybutinin or tolterodine extended-release preparations are commonly prescribed as first-line treatments.

Keywords:  urinary incontinence , anticholinergic drugs , imipramine , M3 selective receptor antagonists , oestrogen , oxybutinin , tolterodine

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 9.95 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1744-1870(06)00100-4

doi:10.1383/wohm.2005.2.6.24

Women's Health Medicine
Volume 2, Issue 6 , Pages 24-25, November 2005

Article Tools